A Secret Weapon For M3541
MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze to evaluate various intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Most important trial goals have been To judge the safety and tolerability of sifalimumab in dermatomyositis or po